Cro

Phamaceutical company focus on innovative drugs including oncology, neurology and autoimmune diseases.

专注医疗投资

Oncology Big Data company headquartered in Beijing. Chinese name 神州医疗 or Digital Health China. US branch in Boston.

diagnostics

CRO based in Shanghai

L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. Founded 38 years ago, L.E.K. employs more than 1,400 professionals around the world. L.E.K. entered China in 1998 and has since become a leading commercial advisor in life sciences and healthcare services practices, covering all aspects of the industry value chain and life cycle. Supported by the Singapore Economic Development Board, L.E.K. established The APAC Life Sciences Centre of Excellence, aiming to provide life sciences companies in APAC with useful insights and practical knowledge, including best practices from other markets around the world. For more information, go to www.lek.com

Mabwell, founded in 2017 in Zhangjiang District of Shanghai, is an innovation-based bio-pharmaceutical company with 9 biomedical R&D and manufacturing subsidiaries and a strong, diverse and experienced technical team under its wing. With its world class high-throughput antibody drug discovery platform, well-established pharmaceutical research system and mature process development, the company is dedicated to the R&D and manufacturing of therapeutic monoclonal antibodies, long acting recombinant protein and other new macromolecular drugs. Currently, 30 different drugs for tumor, autoimmunity, infection resistance and ophthalmology are being developed at various stages, among which 1 is cleared for production and 6 are in clinical research with 4 in key clinical stage. Guided by an innovation-driven strategy, the company has actively pushed for commercialization with a production facility built in line with both Chinese and Western GMP standards already up and running in Taizhou, Jiangsu province. Another large-scale industrial base in Shanghai is under construction. The first drug variety will be on the market in 2020 and the number will go up to 4 (or more) in 2023, Mabwell closed series A financing of 1.97 Billion Yuan at April, 2020, demonstrating the company’s ambition to become a leading bio-pharmaceutical enterprise in China.

High-throughput Human Disease and Tissue Models

MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.